RegulatoryApr 29, 2026, 04:49 PM
NBY to Restate 2025 Financials; Warrant Liability up to $639.1M
AI Summary
NovaBay Pharmaceuticals, Inc. announced that its audited consolidated financial statements for the year ended December 31, 2025, should no longer be relied upon due to an accounting error related to pre-funded warrants. This error will increase the warrant liability from $30.4 million to $639.1 million and the net loss from $22.1 million to $630.8 million for 2025. The company plans to restate these financials in a Form 10-K/A, noting these are non-cash adjustments.
Key Highlights
- 2025 audited financial statements should no longer be relied upon due to an accounting error.
- Error relates to anti-dilution adjustments for pre-funded warrants issued October 16, 2025.
- Warrant liability as of December 31, 2025, to increase from $30.4M to $639.1M.
- Net loss for 2025 to increase from $22.1M to $630.8M due to the error.
- Adjustments are non-cash and do not impact cash, revenue, or operating income.
- Company intends to restate financials in a Form 10-K/A for December 31, 2025.
- Pre-funded warrants expected to be reclassified from liability to equity in Q1 2026.